ALGO experienced a 16.57% quarter-over-quarter decline due to product transitions and fluctuations in the market.

As of November 14, 2025, ALGO experienced a 3.16% decrease over the past 24 hours, bringing its price to $0.1622. Over the previous week, ALGO fell by 8.77%, declined 8.57% in the past month, and saw a 51.51% drop over the last year.

During its Q3 2025 earnings presentation, Alargo Pharmaceuticals emphasized a significant product shift. The company is phasing out Akaroid in favor of its third product, NHD (Novo Hélicine Dépôt), which has now received sales approval. NHD has shown impressive results, with gross sales rising nearly 80% year-over-year and already generating more revenue than Akaroid. This success is credited to a focused approach of collaborating directly with physicians to promote NHD.

AXI’s optimization strategies are also producing positive outcomes. Although sales volume has dropped sharply—about 60% lower as of September 25 compared to the average in Q1 2025—this is a result of deliberately removing low-margin items from the lineup since April 2025. The profit margin per unit has more than doubled during this timeframe. Furthermore, the group’s EBITDA margin improved by roughly one percentage point, thanks to the reduction in low-margin AXI sales.

ARCO Pharma is implementing a strategic overhaul to boost its competitive edge. The company is prioritizing rebranding, better communicating product benefits, and highlighting the distinctive strengths of its manufacturing process to pharmacists, who play a crucial role in distribution. Medical educators are being brought in to train both sales staff and pharmacists on the scientific advantages of ARCO’s products.

Experts believe that moving away from low-margin products and concentrating on core offerings could help expand margins over the long term. Nonetheless, the current decrease in sales volume and ongoing transformation expenses present obstacles to short-term revenue growth.